Lamotrigine ER tablet 50mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioequivalence
Conditions
Bioequivalence
Trial Timeline
Jan 10, 2018 → Feb 21, 2018
NCT ID
NCT05145608About Lamotrigine ER tablet 50mg
Lamotrigine ER tablet 50mg is a phase 1 stage product being developed by Alembic Pharmaceuticals for Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT05145608. Target conditions include Bioequivalence.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05145608 | Phase 1 | Completed |
Competing Products
20 competing products in Bioequivalence